- Home
- PYXS
PYXS
Pyxis Oncology Inc.
as 04-01-2025 4:00pm EST
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | N/A | IPO Year: | 2021 |
| Target Price: | $9.20 | AVG Volume (30 days): | 482.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.32 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.90 - $6.18 | Next Earning Date: | 03-18-2025 |
| Revenue: | $16,146,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Pyxis Oncology Inc. News
PYXS Breaking Stock News: Dive into PYXS Ticker-Specific Updates for Smart Investing
GlobeNewswire
8 days ago
Pyxis Oncology to Present New Preclinical Data Supporting Development of First-In-Concept ADC Targeting EDB+FN in Tumor Microenvironment at AACR 2025
GlobeNewswire
15 days ago
Pyxis Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
GlobeNewswire
a month ago
Pyxis Oncology to Participate at the Leerink Partners Global Healthcare Conference
GlobeNewswire
a month ago
Pyxis Oncology Granted FDA Fast Track Designation for PYX-201 Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer
Simply Wall St.
a month ago
Will Pyxis Oncology (NASDAQ:PYXS) Spend Its Cash Wisely?
GlobeNewswire
2 months ago
Pyxis Oncology Initiates New PYX-201 Combination Trial and Initiates Cohort Expansions of Ongoing Monotherapy Trial
TipRanks
3 months ago
Pyxis Oncology price target lowered to $8 from $10 at RBC Capital
GlobeNewswire
3 months ago
Pyxis Oncology Announces Portfolio Prioritization, Focusing Resources on its Lead Clinical Program, PYX-201
Compare PYXS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PYXS Pyxis Oncology Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.